You just read:

AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries

News provided by

AcelRx Pharmaceuticals, Inc.

29 Aug, 2016, 07:00 ET